A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Who Have Fallen Recently and Have Muscle Weakness

Trial Profile

A Phase 2 Randomized Study to Investigate the Efficacy and Safety of LY2495655 Versus Placebo in Older Patients Who Have Fallen Recently and Have Muscle Weakness

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2015

At a glance

  • Drugs Landogrozumab (Primary)
  • Indications Muscle weakness
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 29 Mar 2015 Results presented at the 2015 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 19 Nov 2014 New trial record
    • 12 Sep 2014 Primary endpoint Change in appendicular Lean Body Mass has been met, according to an abstract presented at the 36th annual meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top